Bronchial Hyperresponsiveness News and Research

RSS

Understanding asthma: The surprising influence of gut bacteria

The role of specific gut microbes in asthma.

15 Nov 2023

IL-9 identified as contributor to viral spread and airway inflammation in COVID-19

Researchers used a K18-hACE2 transgenic (ACE2.Tg) mouse model to demonstrate that interleukin-9 (IL-9).

13 Jul 2023

People with asthma could be negatively affected by increased disinfectant use in the COVID-19 era

Those with asthma are experiencing less asthma control related to an increase in using household disinfectants -- known asthma triggers -- because of COVID-19, according to a survey co-conducted by University of Illinois Chicago researchers.

12 Feb 2021

Women more likely to be hospitalised after asthma emergency care

US research shows that women who attend the emergency department with acute asthma are almost twice as likely to be admitted to hospital than men despite several measures of asthma control, treatment and severity being more favourable in women.

21 May 2015

Site of eosinophilic inflammation important in asthma control

The site of eosinophilic inflammation, whether local, systemic or both, has a significant effect on lung function, bronchial hyperresponsiveness and asthma control, study findings show.

22 Jul 2014

Cockroaches can trigger allergy and asthma attacks

In recognition of National Asthma and Allergy Awareness Month, celebrated in May, the National Pest Management Association (NPMA) is reminding people that cockroaches can trigger asthma and allergy attacks, along with other pertinent diseases.

15 May 2012

CMS assigns J-code for Pharmaxis ARIDOL Bronchial Challenge Test Kit

Pharmaxis, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific billing code, or J-code, for ARIDOL (mannitol inhalation powder) Bronchial Challenge Test Kit.

4 Jan 2012

New omalizumab medication may reduce seasonal asthma attacks in children

A new anti-asthma medication dramatically reduced increases in seasonal asthma attacks in children and young adults with allergic asthma, according to a multi-institutional study involving a UT Southwestern Medical Center physician.

17 Mar 2011

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for respiratory and immune disorders, will present ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, at the 2010 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), November 11-16 in Phoenix, AZ.

11 Nov 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

New clinical predictors required to determine future asthma attacks

Screening tests used to predict asthma activity in patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens, UT Southwestern Medical Center physician report.

1 Sep 2009

FDA accepts Pharmaxis’ Aridol NDA for review

Pharmaxis has announced it had received notification from the United States Food and Drug Administration (FDA) that the New Drug Application (NDA) for its mannitol bronchial challenge test Aridol has been accepted for standard review. The FDA will advise the result of the review on 27 December 2009.

13 May 2009

Pharmaxis announces NDA filing for Aridol

Pharmaxis, Inc., a wholly owned subsidiary of Pharmaxis Ltd , an emerging respiratory specialty pharmaceutical company, announced today that it has filed a New Drug Application (NDA), electronically, with the U.S. Food and Drug Administration (FDA) for Aridol (mannitol bronchial challenge test).

3 Mar 2009

Variation in CHI3L1 gene increases risk of asthma

A tiny variation in a gene known as CHI3L1 increases susceptibility to asthma, bronchial hyperresponsiveness and decline in lung function, researchers report early online in the New England Journal of Medicine.

10 Apr 2008

Bronchial thermoplasty offers significant improvement for asthmatics

Asthmatic patients showed significant improvement in peak expiratory flow, airway responsiveness and number of symptom-free days after treatment with bronchial thermoplasty, a new procedure designed to reduce the ability of airway smooth muscle to narrow from inflammation.

3 May 2006